Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.

Graft Failure Clinical Trial

Official title:

An Open Label, Single Arm, Multicentre, Proof of Concept, Phase 2 Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04731298
• Other study ID #: NI-0501-12
• Status: Terminated
• Phase: Phase 2
• Start date: May 25, 2021
• Est. completion date: April 21, 2022

Study information

• Verified date: December 2023
• Source: Swedish Orphan Biovitrum
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed as an open-label, single arm, proof of concept study in order to determine the appropriate emapalumab dosing regimen neutralizing IFNγ in patients at risk of GF. Patients presenting CXCL9 levels above a defined threshold and other clinical criteria will be eligible to receive emapalumab. Both children and adults, with malignant and non-malignant underlying diseases, receiving allo-HSCT who are at high risk of GF as defined in the inclusion criteria will be included in the study. The main objective of the study is to determine the appropriate emapalumab dose regimen neutralizing interferon gamma (IFNγ) activity to pre-empt graft failure post allo-HSCT in a population with various underlying diseases and at high risk of graft failure (GF). Maximum 3 cohorts are foreseen to determine the appropriate dose regimen to pre-emptively treat patients at risk of primary GF. Emapalumab will be administered by IV infusion and treatment will last up to 56 days (15 infusions) or until evidence of engraftment. The study is expected to last approximately 3 years from screening to the last follow-up phone call for each patient.

Description:

This study is designed as an open-label, single arm, proof of concept study in order to determine the appropriate emapalumab dosing regimen neutralizing IFNγ in patients at risk of GF. Patients presenting CXCL9 levels above a defined threshold and other clinical criteria will be eligible to receive emapalumab. Both children and adults, with malignant and non-malignant underlying diseases, receiving allo-HSCT who are at high risk of GF as defined in the inclusion criteria will be included in the study. The main objective of the study will be to determine the appropriate emapalumab dose regimen neutralizing interferon gamma (IFNγ) activity to pre-empt graft failure post allo-HSCT in a population with various underlying diseases and at high risk of graft failure (GF). Maximum 3 cohorts are foreseen to determine the appropriate dose regimen to pre-emptively treat patients at risk of primary GF. Emapalumab will be administered by IV infusion over 1 to 2 hours depending on the volume of the infusion. Treatment will last up to 56 days (15 infusions) or until evidence of engraftment. The study is comprised of the following study periods: screening (Day -21 to Day -8), allogeneic HSCT Day 0, monitoring period for primary GF (Day 1 up to Day 42), extended monitoring for secondary GF (up to Day 98), treatment period (up to 56 days) and follow-up period of 3 years after HSCT. The main objective of this proof of concept study is: • To determine the appropriate emapalumab dose regimen neutralizing interferon gamma (IFNγ) activity to pre-empt graft failure post allogeneic hematopoietic stem cell transplantation (HSCT) in a population with various underlying diseases and at high risk of graft failure (GF) The following objectives will support the dose selection: - To describe the Pharmacokinetic (PK) and Pharmacodynamic (PD) profiles of emapalumab post allogeneic HSCT (allo-HSCT) - To assess the efficacy of emapalumab to pre-empt GF post allo-HSCT - To assess the safety of emapalumab to pre-empt GF post allo-HSCT - To assess the immunogenicity of emapalumab post allo-HSCT Exploratory objectives will be: • To evaluate further data on the correlation between relevant biomarkers including C-X-C motif chemokine ligand 9 (CXCL9) levels and the risk of GF post allo-HSCT in a population with various underlying diseases and at high risk of GF also in the context of development of a diagnostic test. The study is expected to last approximately 3 years from screening to the last follow-up phone call for each patient.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: April 21, 2022
• Est. primary completion date: April 21, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year and older

Eligibility

Inclusion Criteria:

1. Informed consent form signed by the patient (as required by law) or by the patient's legally authorized representative(s) with the assent of patients who are legally capable of providing it, as applicable

2. Recipients of allogeneic Hematopoietic Stem Cell Transplantation (HSCT) and at high

risk of graft failure (GF) based on at least one of the following criteria:

• Receiving reduced intensity conditioning (RIC) or non-myeloablative conditioning (NMA) combined with a non-malignant disease or with a graft from Bone Marrow (BM)
• Ex vivo T cell depleted graft
• Graft from mismatched unrelated or haploidentical donor
• Graft from Umbilical Cord Blood (UCB)

3. Patients requiring allo-HSCT with the following underlying diseases:

• Malignant disease with high risk of GF, i.e. Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) with primary induction failure, second partial remission or relapse; Chronic Myeloid Leukemia (CML) in blastic phase (circulating blast or blast above 5% in biopsy); Non Hodgkin and Hodgkin Lymphoma and multiple myeloma with primary induction failure, second partial remission or relapse, myelodysplastic syndromes (MDS) and myeloproliferative disorders (MPD) with splenomegaly, myelofibrosis with portal hypertension pre-transplant, MDS/MPD overlap syndromes
• Non-malignant hematological diseases (e.g. autoimmune and metabolic disorders, aplastic anemia, Sickle cell anemia, Fanconi anemia, Diamond-Blackfan anemia, thalassemia, osteopetrosis, Wiskott-Aldrich syndrome, severe combined immunodeficiency, Hemophagocytic lymphohistiocytosis and other immunoregulatory disorders)

4. Male and female patients

5. Children aged at least 1 year and adults. Once the appropriate dose has been determined in one of the three cohorts and safety has been assessed by the Independent Data Monitoring Committee (IDMC), children less than 1 year old may be included in the study.

6. Females of child-bearing potential, defined as all women physiologically capable of becoming pregnant, require use of highly effective contraceptive measures from screening until 6 months after the last study drug administration

Exclusion Criteria:

1. Pregnant (or planning to become pregnant) or lactating female patients

2. Body weight < 3 kg

3. Underlying malignant disease with Karnofsky/Lansky performance status equal or less than 40 or an Eastern Cooperative Oncology Group (ECOG) performance status equal or less than 3

4. Patients presenting CXCL9 levels 10 times above the upper limit of the 95% interval (CI) of the normal range (reported in the CXCL9 assay laboratory manual) within 24 hours prior to HSCT

5. Clinically manifested infections caused by typical and atypical Mycobacteria, Salmonella, Histoplasma capsulatum and Herpes Zoster on the day of HSCT

6. Active or clinical suspicion of latent tuberculosis

7. Concomitant diseases that in the opinion of the Investigator may interfere with the assessment of emapalumab safety or efficacy

8. Receipt of a Bacille Calmette-Guerin (BCG) vaccine within 3 months prior to HSCT

9. Receipt of a live or attenuated live (other than BCG) vaccine within 6 weeks prior to HSCT

10. Current or scheduled administration of therapies known to potentially trigger a cytokine release syndrome within 21 days from HSCT.

11. Patients having received IFN? during the last 2 weeks prior to HSCT and/or who require treatment with IFN?.

12. Patients having received emapalumab during the last 6 months prior to HSCT, unless it is known that emapalumab is no longer detectable.

13. Patients having received kinase inhibitors (Janus kinase inhibitors [JAKi] or bruton tyrosine kinase inhibitors [BTKi]) one week (or 5 half-lives whichever is greater) prior to HSCT.

14. Intolerance to antimicrobial and virus infection prophylaxis.

15. Hypersensitivity to emapalumab or any of the excipients.

16. Ongoing participation in an interventional trial or administration of any investigational drug (within 3 half-lives of the investigational drug) with the exception of interventional trials involving supportive care such as probiotics or antiemetics, graft manipulation, or use of new combinations or new dosing of conventional therapies for conditioning and prophylaxis pre-HSCT.

Related Conditions & MeSH terms

• Graft Failure

Intervention

Drug:
• Emapalumab
Emapalumab is a fully human immunoglobulin G1 (IgG1) anti-IFN? monoclonal antibody that binds to and neutralizes IFN?. Emapalumab binds to both soluble and receptor (IFN?R1)-bound forms of IFN?. Emapalumab is in development for treatment of primary and secondary HLH. The benefit expected from the targeted neutralization of IFN? by emapalumab has been validated by the recent FDA approval of emapalumab for treatment of patients with pHLH who have refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. The safety profile has been assessed as acceptable. Emapalumab will be administered by intravenous infusion over 1 to 2 hours, depending on the volume of the infusion. The first infusion must be performed within 12 hours after CXCL9 levels have been measured above defined threshold. Treatment will last until maximum dose 15 (up to 56 days) or until evidence of engraftment, whichever comes first.

Locations

Country	Name	City	State
Australia	Peter MacCallum Cancer Centre	Melbourne
Australia	Kids Cancer Centre Sydney Children's Hospital	Randwick
Canada	CHU Sainte-Justine	Montréal	Quebec
Israel	The Rambam Academic Hospital	Haifa
Israel	Hadassah Hebrew University	Jerusalem

Sponsors (7)

Lead Sponsor	Collaborator
Swedish Orphan Biovitrum	ABF Pharmaceutical Services GmbH, BioMérieux, Cromsource, Cytel Inc., PRA Health Sciences, Q2 Solutions

Countries where clinical trial is conducted

Australia,  Canada,  Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CXCL9 in Serum	Serum concentration of C-X-C Motif Chemokine Ligand 9 (CXCL9)	From start of treatment to EoS Visit, up to 34 weeks
Primary	Primary Graft Failure (GF)	Number of participants with primary graft failure (GF)	From Hematopoietic stem-cell transplantation (HSCT) [Day 0] up to study termination, approximately 46 weeks
Primary	Secondary GF	Number of participants with secondary GF	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Free & Total Interferon Gamma (IFN?) in Serum	Serum concentration of free and total Interferon gamma (IFN?)	From start of treatment to EoS Visit, up to 34 weeks
Secondary	Emapalumab in Serum - Peak	Peak emapalumab serum concentration	From start of treatment to EoS, up to 34 weeks
Secondary	Ctrough (Emapalumab)	Concentration just before administration	From start of treatment to EoS, up to 34 weeks
Secondary	Exploratory Biomarkers: Ferritin	Ferritin - serum concentration	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	ADA and nAbs	Number of participants developing antibodies against emapalumab (antidrug antibodies [ADA]) and Neutralizing antibodies (nAb)	From Start of treatment until EoS, up to 34 weeks
Secondary	Number of Participants With Mixed Donor Chimerism <10% and <20%	Based on unselected leukocytes and based on sorted T cells	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Number of Participants Receiving Thrombopoietic Agents, Stem Cell Boost, Donor Lymphocyte Infusion (DLI)		From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Number of Participants Receiving a Second Allogeneic HSCT		From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Number of Participants With Poor Graft Function		From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Number of Participants With Event Free Engraftment	defined as absence of GF or graft support	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Number of Participants With Acute and/or Chronic Mild to Severe Graft Versus Host Disease (GvHD)	(grade I to IV)	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Biomarker Levels, in Particular IFNy and CXCL9, as Predictors of Primary and/or Secondary Graft Failure or Acute and/or Chronic GvHD		From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Engraftment Syndrome	Number of participants with engraftment syndrome	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Number of Participants With Endothelial Complications		From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Number of Participants With Relapse, Defined as Cumulative Incidence of Reoccurring Underlying Disease		From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Survival Rate	Number of patients alive at the end of study.	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Body Temperature	Change from baseline in body temperature	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Heart Rate	Change from baseline in heart rate	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Blood Pressure	Change from baseline systolic and diastolic blood pressure	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Body Weight	Change from baseline in body weight	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Hematology: Red Blood Cells (RBC)	Change from baseline in Hematology: red blood cells (RBC)	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Hematology: Hematocrit	Change from baseline in Hematology: hematocrit	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Hematology: Hemoglobin	Change from baseline in Hematology: hemoglobin	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Hematology: Platelets	Change from baseline in Hematology: platelets	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Hematology: White Blood Cells (WBC)	Change from baseline in Hematology: white blood cells (WBC)	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Hematology Differential: Lymphocytes	Change from baseline in Hematology differential: lymphocytes	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Hematology Differential: Monocytes	Change from baseline in Hematology differential: monocytes	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Hematology Differential: Neutrophils	Change from baseline in Hematology differential: neutrophils	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Biochemistry: Ferritin	Change from baseline in Biochemistry: Ferritin	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Biochemistry: Glucose	Change from baseline in Biochemistry: Glucose	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Biochemistry: C-reactive Protein	Change from baseline in Biochemistry: C-reactive protein	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Biochemistry: Sodium	Change from baseline in Biochemistry: Sodium	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Biochemistry: Potassium	Change from baseline in Biochemistry: Potassium	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Biochemistry: Chloride	Change from baseline in Biochemistry: Chloride	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Biochemistry: Calcium	Change from baseline in Biochemistry: Calcium	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Biochemistry: Magnesium	Change from baseline in Biochemistry: Magnesium	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Biochemistry: Phosphate	Change from baseline in Biochemistry: Phosphate	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Biochemistry: Aspartate Aminotransferase (AST)	Change from baseline in Biochemistry: Aspartate aminotransferase (AST)	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Biochemistry: Alanine Aminotransferase (ALT)	Change from baseline in Biochemistry: alanine aminotransferase (ALT)	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Biochemistry: Gamma-glutamyl Transpeptidase (?GT)	Change from baseline in Biochemistry: gamma-glutamyl transpeptidase (?GT)	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Biochemistry: Alkaline Phosphatase (ALP)	Change from baseline in Biochemistry: alkaline phosphatase (ALP)	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Biochemistry: Lactate Dehydrogenase (LDH)	Change from baseline in Biochemistry: lactate dehydrogenase (LDH)	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Biochemistry: Bilirubin	Change from baseline in Biochemistry: bilirubin (total, direct and indirect)	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Biochemistry: Triglycerides	Change from baseline in Biochemistry: triglycerides	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Biochemistry: Cholesterol	Change from baseline in Biochemistry: cholesterol (total and high-density lipoprotein [HDL])	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Biochemistry: Albumin	Change from baseline in Biochemistry: Albumin	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Biochemistry: Creatinine	Change from baseline in Biochemistry: Creatinine	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Biochemistry: Urea	Change from baseline in Biochemistry: Urea	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Activated Partial Thromboplastin (aPTT)	Change from baseline in Coagulation: activated partial thromboplastin (aPTT)	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Prothrombin Time (PT)	Change from baseline in Coagulation: prothrombin time (PT)	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Urinalysis: Glucose	Change from baseline in Urinalysis: Glucose	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Urinalysis: Blood	Change from baseline in Urinalysis: Blood	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Urinalysis: Protein	Change from baseline in Urinalysis: Protein	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Urinalysis: Leucocytes	Change from baseline in Urinalysis: Leucocytes	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Urinalysis: Ketones	Change from baseline in Urinalysis: Ketones	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Urinalysis: pH	Change from baseline in Urinalysis: pH	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in Urinalysis: Specific Gravity	Change from baseline in Urinalysis: specific gravity	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Number of Subjects With Change in Donor Chimerism		From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change in HLA Antibodies	Change from baseline in HLA antibodies against donor cells	From HSCT (Day 0) up to study termination, approximately 46 weeks
Secondary	Change From Baseline in Minimal Residual Disease (MRD)	Only in patients presenting malignant disease	From HSCT (Day 0) up to study termination, approximately 46 weeks